论文部分内容阅读
目的观察注射用血凝酶(巴曲亭)与垂体后叶素联合治疗支气管扩张大咯血的临床疗效。方法选取医院收治的支气管扩张大咯血患者76例作为研究对象,随机分为对照组和观察组,每组38例。对照组单纯采用垂体后叶素进行治疗,观察组采用巴曲亭联合垂体后叶素进行治疗。观察2组患者的临床治疗效果与不良反应发生率。结果观察组总有效率为97.37%显著高于对照组的73.68%(P<0.01);观察组不良反应发生率为10.53%低于对照组的31.58%(P<0.05)。结论巴曲亭联合垂体后叶素治疗支气管扩张大咯血患者效果显著,可改善患者的临床症状,降低不良反应发生率,值得临床推广应用。
Objective To observe the clinical efficacy of injectable hemagglutinin (batrutang) and pituitrin in the treatment of bronchiectasis and hemoptysis. Methods Totally 76 patients with bronchiectasis and hemoptysis admitted to hospital were randomly divided into control group and observation group, with 38 cases in each group. The control group was treated with pituitrin alone, and the observation group was treated with Barthenting combined with pituitrin. The clinical efficacy and incidence of adverse reactions in the two groups were observed. Results The total effective rate in the observation group was 97.37%, which was significantly higher than that in the control group (73.68%, P <0.01). The adverse reaction rate in the observation group was 10.53%, which was lower than that in the control group (31.58%, P <0.05). Conclusions Batroxing combined with pituitrin treatment of patients with bronchiectasis and hemoptysis significant effect, can improve the clinical symptoms and reduce the incidence of adverse reactions, it is worth promoting the clinical application.